Comparison · NCT03690388-deaths
Cabozantinib vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cabozantinib vs Placebo: deaths from any cause. Trial comparisons, record NCT03690388-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03690388-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.136 | 0.0867 | 0.207 | wilson | |
| Risk in group 2 | 0.226 | 0.14 | 0.344 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0898 | -0.218 | 0.0219 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.602 | 0.318 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.54 | 0.246 | 1.18 | log | |
| Number needed to treat, for one fewer death from any cause on Cabozantinib than on Placebo | 11.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cabozantinib | cabozantinib (60 mg) once daily orally (qd)~Cabozantinib: Tablets containing 60-mg or 20-mg cabozantinib once daily orally. | 17 | 125 | EG000 |
| Group 2 | Placebo | placebo once daily orally (qd)~Placebo: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally. | 14 | 62 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 1 year, 8 months.
Source ClinicalTrials.gov
Trial
- Title
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- NCT number
- NCT03690388
- Phases
- PHASE3
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- Cabozantinib, Placebo
- Lead sponsor
- Exelixis
- Results first posted
- 2023-05-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03690388?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03690388-deaths